United Therapeutics Corporation (NASDAQ:UTHR) Chairperson and CEO Martine A. Rothblatt executed the sale of 9,500 common shares on June 9, 2026, realizing approximately $5.218 million in proceeds. The transactions, facilitated through the exercise of stock options and subsequent sales, were conducted under a pre-arranged Rule 10b5-1 trading plan established in November 2025. This activity follows a significant year-over-year stock appreciation of 96.6% and coincides with the release of first-quarter financial results that fell short of consensus estimates, alongside the announcement of a positive Phase 3 clinical trial outcome for its Tyvaso treatment.
Rothblatt sold the 9,500 shares at prices ranging from $544.15 to $552.95 per share, resulting in an aggregate value of $5,218,533. Prior to the sales, she acquired the identical number of shares by exercising stock options at $146.03 per share, totaling $1,387,285. The Rule 10b5-1 plan, adopted on November 7, 2025, remains active until the earlier of the exercise of 1,734,410 stock options expiring on March 15, 2027, or December 31, 2026. Following these transactions, Rothblatt directly holds 40,513 shares, with additional indirect holdings through family trusts and her spouse.
The insider activity occurs against a backdrop of substantial stock performance. According to InvestingPro data, United Therapeutics shares have delivered a 96.6% return over the past year. The platform indicates the stock is currently slightly overvalued relative to its Fair Value, with 12 additional ProTips available to subscribers. Market data shows the stock closed at $544.10, down $9.04 or 1.63% on the day, with no movement in after-hours trading.
Financially, United Therapeutics reported first-quarter revenue of $781.5 million, which fell short of the consensus estimate of $797.4 million. Tyvaso revenues were $457.5 million, missing the expected $478.6 million, and net income was $274.9 million, below the anticipated $320.5 million.
Despite the earnings miss, the company announced that its TETON-1 phase 3 study of nebulized Tyvaso in idiopathic pulmonary fibrosis met its primary endpoint. The study demonstrated that Tyvaso preserved lung function and reduced the risk of clinical worsening events, with results published in the New England Journal of Medicine.
Analyst sentiment remains mixed. TD Cowen reiterated its Buy rating on United Therapeutics, maintaining a price target of $675.00. Meanwhile, BTIG reiterated a Neutral rating on the stock following the first-quarter earnings miss.
United Therapeutics has also partnered with Varda Space Industries to explore microgravity-based pharmaceutical processing for treatments targeting rare pulmonary diseases. This collaboration will involve conducting pharmaceutical processing aboard Varda’s orbital manufacturing platform during missions to low Earth orbit.